Welcome to our dedicated page for Canopy Growth news (Ticker: CGC), a resource for investors and traders seeking the latest updates and insights on Canopy Growth stock.
Canopy Growth Corporation develops and sells cannabis products for adult-use and medical markets, with common shares trading as CGC on Nasdaq and WEED on the TSX. Company updates frequently cover Canadian brand activity across Tweed, Deelish, 7ACRES, DOJA, Deep Space and related formats including flower, pre-rolls, vapes, softgels and minor cannabinoid products.
News also centers on medical cannabis services through Canada House Clinics and the Abba Medix online channel, Storz & Bickel vaporization devices, operating and financial results, capital-structure actions, shareholder voting matters and governance changes. Canopy Growth also discloses its unconsolidated, non-controlling interest in Canopy USA as exposure to the U.S. THC market.
Summary not available.
Summary not available.
On April 14, 2023, Canopy Growth (NASDAQ: CGC, TSX: WEED) announced an Exchange Agreement with Greenstar Canada Investment Limited Partnership, a subsidiary of Constellation Brands, to extinguish approximately C$100 million (around USD$73.9 million) in unsecured notes due 2023. The agreement involves a cash payment for accrued interest and a Promissory Note of C$100 million, due December 31, 2024, with an interest rate of 4.25%. Following this transaction, Canopy Growth plans to create a new class of Exchangeable Shares that will be convertible into common shares. This strategic move aims to preserve cash and reduce annual expenses as Canopy Growth looks to strengthen its financial position.
Canopy Growth Corporation (CGC) announced a US$150 million offering of senior unsecured convertible debentures with an institutional investor. The initial purchase amounts to US$100 million, with an additional US$50 million contingent on specific conditions. These convertible debentures, bearing an interest rate of 5.0% per annum, will convert into common shares at 92.5% of the average price prior to conversion. Canopy aims to utilize the proceeds for working capital and corporate purposes. Notably, the debentures will not be listed on any exchange, and repayment will occur in common shares on the Maturity Date, February 28, 2028.
Canopy Growth Corporation (CGC) announced a transformation of its Canadian operations to an asset-light model, focusing on profitability. The company aims to cut costs by $140-$160 million over the next 12 months by downsizing its production footprint and reducing headcount by approximately 60%, affecting around 800 positions. Q3 FY2023 financial results showed net revenue of $101 million, down 28% year-over-year, and a net loss of $267 million. Despite challenges, management forecasts positive Adjusted EBITDA in FY2024. The company expects pre-tax charges of $425-$525 million due to restructuring, impacting the current quarter and first half of FY2024.
Canopy Growth Corporation (CGC) will ring the Nasdaq opening bell on December 12, 2022, with CEO David Klein leading the ceremony. This event highlights Canopy's status as a Nasdaq-listed company and its ongoing efforts to establish itself as a leading North American cannabis firm. Klein expressed pride in the company's progress and a commitment to harnessing cannabis's potential for improving lives. The ceremony can be viewed live at 9:15 a.m. ET from the Nasdaq MarketSite Tower in New York City.
Canopy Growth Corporation (CGC) reported Q2 FY2023 financial results, showing a 10% revenue decline year-over-year at $117.9 million, attributed to heightened competition and strategic divestitures. However, net revenue increased 7% sequentially from Q1 FY2023. Notably, BioSteel achieved a 299% revenue growth compared to the prior year. The company announced its strategic plan for U.S. market entry through Canopy USA, which is expected to enhance growth opportunities and profitability following its acquisitions of Acreage, Jetty, and Wana.
Canopy Growth Corporation (NASDAQ: CGC) will announce its financial results for the second quarter of fiscal year 2023, ending September 30, 2022, on November 9, 2022, before market opening. Alongside the results, Canopy Growth will hold a live audio webcast with CEO David Klein and CFO Judy Hong at 10:00 AM ET on the same day. Shareholders can submit questions from November 2 to November 8, 2022. This session will provide insights into the company's performance, future strategies, and shareholder engagement.
On October 24, 2022, Canopy Growth and Canopy USA completed a reorganization resulting in Canopy USA acquiring all of Canopy Growth's interests in TerrAscend Corp. This included 38,890,570 Exchangeable Shares and significant equity options and warrants, resulting in a 100% decrease of Canopy Growth's direct interest. Post-reorganization, Canopy Growth no longer owns any securities in TerrAscend, while Canopy USA controls 100% of the Exchangeable Shares and approximately 19.9% of Common Shares. Future plans regarding these securities remain uncertain, depending on market conditions.
Canopy Growth Corporation announced a strategic move to create a new holding company, Canopy USA, designed to fully capture its U.S. cannabis investments, targeting a market projected to exceed $50 billion by 2026. The formation of Canopy USA enables the acquisition of Acreage Holdings and optimizes the company's balance sheet to facilitate growth opportunities. Canopy aims to consolidate its U.S. cannabis assets, enhancing revenue and operational synergies while positioning itself to benefit from future U.S. federal legalization of cannabis.